Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays cut their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Price Performance

Shares of Cellectis stock opened at $1.71 on Friday. Cellectis has a 52 week low of $1.69 and a 52 week high of $3.77. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $2.08. The stock has a market cap of $94.77 million, a PE ratio of -1.31 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the prior year, the company earned ($0.31) earnings per share. As a group, sell-side analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Long Focus Capital Management LLC boosted its position in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the period. Principal Financial Group Inc. raised its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. First Affirmative Financial Network purchased a new stake in Cellectis in the 3rd quarter worth about $45,000. Finally, XTX Topco Ltd acquired a new stake in Cellectis during the 2nd quarter worth about $29,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.